Publications Chair & Editor-in-Chief:
Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors:
Brandon Aden, MD
John A. Fromson, MD
Jack Woodside, MD
ASAM Staff Producer:
Zach Caruso
This Week in Addiction Medicine is an audio summary of the recent top stories and research articles from the field of addiction medicine. Intended to serve as an accompaniment to the ASAM Weekly newsletter or as a stand-alone resource, This Week covers recent publications in addiction medicine research.
Tuesday Sep 20, 2022
Tuesday Sep 20, 2022
Association of Mental Health Burden With Prenatal Cannabis Exposure From Childhood to Early Adolescence
JAMA Pediatrics
In this study, the authors credit longitudinal data from the Adolescent Brain Cognitive Development (ABCD) study and investigate whether associations with psychopathology last into early adolescence and past middle childhood. Prenatal Cannabis Exposure (PCE) was found to be associated with lasting vulnerability to psychopathology throughout early adolescence, and this did not change with age. Evidence that the impact of PCE on psychopathology does not improve as children enter adolescence is further warning against the use of this substance in pregnancy.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Sep 13, 2022
Tuesday Sep 13, 2022
Tuesday Sep 13, 2022
Thirty Years of The ASAM Criteria: A Report Card
Psychiatric Clinics of North America
The ASAM Criteria® – the sophisticated system for organizing treatment services and settings with patient care decision rules – defined the infrastructure of addiction care, the types and intensity of treatment, staffing, and service provision for each level of care. For more than 30 years, this led to a national standard in addiction treatment and a leadership role in behavioral health. Beyond the ASAM Criteria, there is ASAM CONTINUUMTM software and the ASAM–CARF Level of Care (LOC) Certification Program, affording a common language and process for improving care. The authors have constructed a report card given the history of the Criteria, with plans for improvement.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Sep 06, 2022
Tuesday Sep 06, 2022
Tuesday Sep 06, 2022
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic
JAMA Psychiatry
During the COVID-19 pandemic, emergency authority allowed expanded telehealth services for MOUD as well as increased take home doses of methadone at OTPs. This study used data from the US Centers for Medicare & Medicaid Services regarding telehealth services for OUD, retention in treatment, and medically treated overdoses. Telehealth services for OUD increased significantly during the pandemic to 20% of beneficiaries compared to 0.6% prepandemic. Receipt of telehealth services was associated with increased MOUD retention (aOR 1.27) and reduced medically treated overdose (aOR 0.67). MOUD (mostly methadone) from an OTP increased during the pandemic to 4.0% from 1.4% prepandemic. The authors conclude that the improved retention and decrease in overdoses associated with telehealth support making these emergency changes permanent.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Aug 30, 2022
Tuesday Aug 30, 2022
Marijuana and hallucinogen use among young adults reached all time-high in 2021
NIDA
2021 MONITORING THE FUTURE PANEL STUDY ANNUAL REPORT
Monitoring the Future
Since 1975, the Monitoring the Future study has annually surveyed substance use behaviors and attitudes among a nationally representative sample of teens. As reported by young adults, marijuana and hallucinogen use in the past year increased significantly in 2021, reaching historic highs in this age group since 1988. Rates of past-month nicotine vaping also continued their general upward trend in 2021, despite leveling off in 2020. Past-month marijuana vaping rebounded to pre-pandemic levels in 2021. Alcohol remains the most used substance among adults in the study. Binge drinking (five or more drinks in a row in the past two weeks) rebounded in 2021 from a historic low in 2020, during the early stages of COVID-19 pandemic. In 2021, high-intensity drinking (having 10 or more drinks in a row in the past two weeks) reached its highest level ever recorded since first measured in 2005.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Aug 23, 2022
Tuesday Aug 23, 2022
Longitudinal Assessments of Neurocognitive Performance and Brain Structure Associated With Initiation of Tobacco Use in Children, 2016 to 2021
JAMA Network Open
Data from the Adolescent Brain and Cognitive Development (ABCD) study was analyzed to assess impact of early initiation (
Tuesday Aug 16, 2022
Tuesday Aug 16, 2022
Tuesday Aug 16, 2022
Adolescent Use of Flavored Non-Tobacco Oral Nicotine Products
Pediatrics
Prevalence of non-tobacco oral nicotine product use among adolescents is unknown. This study calculated prevalence of ever and past 6-month use of nicotine pouches, other non-tobacco oral nicotine products, e-cigarettes, cigarettes, hookah or waterpipe, cigars, cigarillos, and snus among high school students in Southern California between September and December 2021. Generalized linear mixed models tested associations of sociodemographic factors and tobacco-product use with use of any non-tobacco oral nicotine product. Flavored non-tobacco oral nicotine products were the second most prevalent nicotine product used by adolescents in Southern California. They were disproportionately used by certain racial and ethnic, sexual, or gender minority groups and those with a history of nicotine use.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Aug 09, 2022
Tuesday Aug 09, 2022
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder
American Journal of Psychiatry
This was a national retrospective cohort study with interrupted time-series analyses that examined the impact of policy changes in March 2020 on buprenorphine treatment for OUD in the Veterans Health Administration, during the year before the start and during the first year of the COVID-19 pandemic. Also examined were trends in the use of telephone, video, and in-person visits for buprenorphine treatment and a comparison of patient demographic characteristics and retention in buprenorphine treatment across the two periods. The number of patients receiving buprenorphine continued to increase after the COVID-19 policy changes, but the delivery of care shifted to telehealth visits, suggesting that any reversal of COVID-19 policies must be carefully considered.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Aug 02, 2022
Tuesday Aug 02, 2022
Associations of cannabis potency with mental ill health and addiction: a systemic review
The Lancet Psychiatry
Cannabis potency, defined as the concentration of Δ9-tetrahydrocannabinol (THC), has increased internationally, which could increase the risk of adverse health outcomes for cannabis users. This is the first systematic review of the association of cannabis potency with mental health and addiction. Overall, use of higher potency cannabis, relative to lower potency cannabis, was associated with an increased risk of psychosis and Cannabis Use Disorder (CUD). Evidence varied for depression and anxiety. The association of cannabis potency with CUD and psychosis highlights its relevance in health-care settings and for public health guidelines and policies on cannabis sales. Standardization of exposure measures and longitudinal designs are needed to strengthen the evidence of this association.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Jul 26, 2022
Tuesday Jul 26, 2022
Drug Overdose Deaths, by Selected Sociodemographic and Social Determinants of Health Characteristics — 25 States and the District of Columbia, 2019–2020 🔓
CDC Morbidity and Mortality Weekly Report
This CDC report shows that as overdose deaths exploded during the pandemic, racial disparities widened. Specifically, while overall overdose deaths increased by 30% from 2019 to 2020, rates spiked much more among Black, American Indian, and Alaska Native populations than among white, Asian/Pacific Islander, and Hispanic people. Overdose deaths had been rising for decades before the pandemic, and they continued to climb into 2021, reaching more than 107,000 that year. Disparities were emerging in the pre-pandemic years and are expected to keep growing without concentrated efforts to stem them. Not surprisingly, the deaths were broadly driven by illicit fentanyl, though deaths attributed to other drug types, including stimulants like methamphetamine, have also been rising in recent years. The vast majority of people who died did not have evidence of past treatment for substance use disorder. White people who died appeared to have higher rates of treatment than people of other races and ethnicities.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
Tuesday Jul 19, 2022
Tuesday Jul 19, 2022
Tuesday Jul 19, 2022
Preaddiction—A Missing Concept for Treating Substance Use Disorders
JAMA Psychiatry
This opinion piece calls for intervention with mild to moderate SUD (as defined by DSM V) to interrupt the progression to severe SUD. They suggest the term preaddiction, similar to the concept of prediabetes. Engaging the public in screening and intervening with prediabetes has succeeded in halting progression. For SUD, existing interventions, such as screening and brief intervention and computerized cognitive behavioral therapy could be used. However, they expect a range of medications and social support services will also be needed. It will be necessary for medical and nursing schools to teach recognition and management of SUDs and for there to be adequate reimbursement for these interventions. The example of prediabetes demonstrates that an early intervention program can be effective.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM

ASAM, founded in 1954, is a professional medical society representing over 7,000 physicians, clinicians, and associated professionals in the field of addiction medicine.
ASAM is dedicated to increasing access and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction.
Visit www.ASAM.org for more information.
Publications Chair & Editor-in-Chief:
Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors:
Brandon Aden, MD
John A. Fromson, MD
Jack Woodside, MD
ASAM Staff Producer:
Zach Caruso
Disclaimer:
This podcast is for informational purposes only and should not be considered health advice.
• We are not responsible for any losses, damages, or liabilities that may arise from the use of this podcast.
• This podcast is not intended to replace professional medical advice.
• The views expressed in this podcast may not be those of the host or the management.